Side-by-side pharmacokinetic comparison
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Primary receptor activity | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Approximate half-life | About 7 days | About 5 days |
| Approximate time to steady state | 4–5 weeks | About 4 weeks |
| Approximate near-clearance after final dose | About 5 weeks | About 25 days |
Why both medications can be dosed weekly
A dosing interval does not need to equal a drug's half-life. Weekly dosing works for both compounds because substantial drug remains at day seven, and each new dose overlaps with what remains from prior doses. That repeated overlap produces accumulation until input and elimination reach a repeating weekly pattern.
See the source-level profiles for semaglutide and tirzepatide, or compare the curves directly with the free half-life calculator.
What the half-life difference changes
Between-dose decline
With all other factors held equal, a compound with a 7-day half-life retains a larger fraction of a dose after one week than a compound with a 5-day half-life. Real medications are not interchangeable, however, because dose, potency, receptor targets, and exposure-response relationships differ.
Time after stopping
A common pharmacokinetic rule of thumb is that most of a drug is eliminated after roughly five half-lives. That yields an estimate of about five weeks for semaglutide and about 25 days for tirzepatide. These are estimates, not guarantees for an individual.
Steady-state timing
Both medications build gradually. Tirzepatide reaches steady state after approximately four weeks of weekly administration, while semaglutide labeling describes steady-state exposure after four to five weeks.
Half-life does not tell you which medication is better
Half-life answers one narrow question: how quickly does concentration decline? It does not independently answer which medication produces more weight loss, which is better tolerated, or which is appropriate for a specific patient. Those questions require clinical trial evidence and individualized prescribing decisions.
Missed-dose rules are also different
Do not infer a missed-dose rule from half-life alone. Product labels provide brand-specific instructions. For tirzepatide, read the official 4-day missed-dose rule explained. For any prescribed GLP-1 medication, follow the current label and your clinician's instructions.
Frequently asked questions
Which has a longer half-life, semaglutide or tirzepatide?
Semaglutide has the longer elimination half-life at approximately 1 week, compared with approximately 5 days for tirzepatide.
How long do semaglutide and tirzepatide stay in the body?
Using the common estimate of about 5 half-lives for near-complete elimination, semaglutide may take roughly 5 weeks and tirzepatide roughly 25 days after the final dose. Individual clearance varies.
Does a longer half-life mean semaglutide works better?
No. Half-life describes elimination speed, not overall effectiveness. Efficacy also depends on receptor activity, dose, adherence, population, and clinical endpoint.